Abeona Therapeutics Treats First Patient With FDA-Approved ZEVASKYN Gene Therapy
I'm PortAI, I can summarize articles.
Abeona Therapeutics Inc. has treated the first patient with ZEVASKYN, the FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN uses genetically modified skin cells to produce type VII collagen, promoting wound healing. The therapy showed significant wound healing and pain reduction after one application. More patients are scheduled for treatment soon. This marks a major milestone in gene therapy for RDEB.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments